tangental re. the Pfizer/OSIP farnesyl transferase inhibitors. Nice to see work from DNAX (SPRI), one of the old-time biotechs.....
Thursday May 18, 8:31 am Eastern Time
Company Press Release
SOURCE: Strategic Research Institute
Farnesyl Transferase Inhibitors as Potential
Anti-Cancer Agents to Headline Anti-Cancer Drug
Discovery & Development Conference June 12 & 13,
2000 in Princeton, N.J.
PRINCETON, N.J., May 18 /PRNewswire/ -- Late-breaking advances in anti-cancer research on farnesyl transferase, novel
protein kinase, metalloproteinase, and anti-angiogenic inhibitors at the pre-clinical and clinical stages will be the focus of a new
pharma conference series to take place in Princeton, NJ on June 12-13, 2000, announces Strategic Research Institute.
The presentations on farnesyl transferase inhibitors will be given by Dr. Jay Gibbs of Merck & Co. and Dr. Paul Kirschmeier of
Schering-Plough Research Institute. Merck & Co. will be presenting pre-clinical data that supports farnesyl transferase
inhibitors' effectiveness against a variety of human cancers, a hypothesis that is currently being tested in the clinic.
Schering-Plough Research Institute will present data dealing with the G2-M effects of the farnesyl transferase inhibitors, and
how this may be important for their chemotherapeutic activity alone or in combination with other agents like taxol.
The meeting, divided into four discrete sections, 1) identifying new targets, 2) novel anti-tumor agents, 3) protein kinase
inhibitors, and 4) anti-angiogenic inhibitors, will feature as speakers, prominent pharmaceutical, biotechnology, and academic
scientists revealing their newest findings.
Also presenting papers on behalf of the industry will be AstraZeneca, Hoffmann-La Roche, Bristol-Myers Squibb,
Parke-Davis, Genentech, Glaxo Wellcome, Pharmacia Corp./Searle, Sugen, ImClone Systems, British Biotech and Cell
Pathways, while the National Cancer Institute, Duke University Medical Center, Georgetown University, and Columbia
University will represent the academic community.
Other highlights of the program include:
-- Dr. Larry Witte of ImClone Systems will present compelling new data on
therapeutic anti-angiogenesis antibodes against VEGFR2 & VE-Cadherin.
-- Dr. Duncan Walker of Hoffman-La Roche will discuss the application of
genomics tools for pre-clinical drug discovery in cancer.
-- The results of a phase I clinical trial of COL-3, a Matrix
Metalloproteinase Inhibitor, will be presented by the National Cancer
Institute.
To receive the full agenda and/or register for the conference, please contact Jon E. Liong of Strategic Research Institute at
jliong@srinstitute.com or 212-967-0095, ext. 243 (please include name, corporate affiliation, mailing address, and fax
number).
For information on exposition, please contact Mark Alexay at malexay@hotmail.com.
SOURCE: Strategic Research Institute |
